ArticleNature medicine2017
A tripartite complex of suPAR, APOL1 risk variants and α
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 3 pooled it
17.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 3 syntheses or guidelines pooled it, 201 citations in OpenAlex.
- Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.The Journal of clinical investigation · 2022Pooled it
- Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.Communications biology · 2021Pooled it
- Pooled it
- Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study.ESC heart failure · 2025Trial
- An inducible co-stimulator ligand (ICOSL)-based peptide therapy for proteinuric kidney diseases targeting αvβ3 integrin.Molecular biomedicine · 2026Article
- Potential Role of the Urokinase-Type Plasminogen Activator Receptor-Integrin β3 Axis in Podocyte Adhesion Instability and Loss.Kidney international reports · 2026Article
- APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.International urology and nephrology · 2026Review
- Sotagliflozin, suPAR, and Cardiovascular Outcomes in Patients With Diabetes and Heart Failure: A SOLOIST-WHF Ancillary Study.Journal of cardiac failure · 2026Observational
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.Journal of the American Heart Association · 2026Article
- uPAR/suPAR Signaling and Organ Crosstalk in Cardiovascular-Kidney-Metabolic Syndrome.Circulation research · 2026Review
- Precision Diagnosis in APOL1 Kidney Disease With the p.N264K M1 Protective Variant.JAMA network open · 2026Article
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease.Diabetes care · 2026Article
- The role of suPAR and related proteins in kidney, heart diseases, and diabetes.The Journal of clinical investigation · 2026Review
- APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years.BMC nephrology · 2025Review
- APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2025Article
- Soluble urokinase receptor is a kidney-specific vasoconstrictor.EBioMedicine · 2025Article
- Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025Review
- HIV-1 Nef synergizes with APOL1-G1 to induce nephrocyte cell death in HIV-related kidney diseases.Disease models & mechanisms · 2025Article
- Review
86 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 11 institutions in 3 countries.
Salim S HayekEmory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0003-0180-349X
Kwi Hye KohDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Morgan E GramsWelch Center for Prevention and Johns Hopkins Bloomberg School of Public Health, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USA.
Changli WeiDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Yi-An KoDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.
Jing LiDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Beata SamelkoDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Hyun LeeCenter for Biomolecular Science and Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, USA.
Ranadheer R DandeDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Ha Won LeeDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Eunsil HahmDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.ORCID http://orcid.org/0000-0002-0343-7473
Vasil PeevDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Melissa TracyDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Nicholas J TardiDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Vineet GuptaDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.ORCID http://orcid.org/0000-0001-6987-2550
Mehmet M AltintasDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Garrett GarborcauskasHarvard Medical School and Division of Nephrology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Nikolina StojanovicHarvard Medical School and Division of Nephrology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Cheryl A WinklerMolecular Genetic Epidemiology Section, Basic Research Laboratory, Basic Science Program, NCI, Leidos Biomedical Research, Frederick National Laboratory, Frederick, Maryland, USA.ORCID http://orcid.org/0000-0001-5552-0917
Michael S LipkowitzDivision of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC, USA.
Adrienne TinWelch Center for Prevention and Johns Hopkins Bloomberg School of Public Health, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USA.
Lesley A InkerDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Martin ZeierDivision of Nephrology, Ruprecht Karls University, Heidelberg, Germany.
Barry I FreedmanDepartment of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Jeffrey B KoppKidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Karl SkoreckiRappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel.
Josef CoreshWelch Center for Prevention and Johns Hopkins Bloomberg School of Public Health, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USA.
Arshed A QuyyumiEmory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Sanja SeverHarvard Medical School and Division of Nephrology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Jochen ReiserDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Rush University Medical Center · USEmory University · USHarvard University · USJohns Hopkins University · USTufts Medical Center · USGeorgetown University · USHeidelberg University · DELeidos (United States) · USNational Institutes of Health · USTechnion – Israel Institute of Technology · ILWake Forest University · US
Funding
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0MSerious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI EASLEY, KIRK · 2008 to 2019
$17.9MFocal Segmental Glomerulosclerosis: Genetics & MechanismsZIADK043308 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOPP, JEFFREY BURNETT · 2009 to 2024
$15.7MVascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2010 to 2015
$11.0MGenetics of Renal Disease in African AmericansZIABC010022 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINKLER, CHERYL · 2009 to 2022
$8.9MMulti-Omics and Chronic Kidney Disease: Correlation with HistologyR01DK108803 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Morgan Erika Grams, EUGENE P. RHEE · 2016 to 2026
$6.4MCell therapy for diabetic peripheral neurovascular complicationsDP3DK094346 · NIDDK · EMORY UNIVERSITY · PI CHENG, XIAODONG, YOON, YOUNG-SUP · 2011 to 2011
$6.1MThe role of the renin-angiotensin-endothelial pathway in ADRF1AG051633 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, QUYYUMI, ARSHED A · 2015 to 2017
$6.0MProteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6MAdverse effects of RBC transfusions: A unifying hypothesisR01HL095479 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2009 to 2017
$5.2MMetabolomics of subclinical and clinical cardiovascular diseaseP20HL113451 · NHLBI · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2012 to 2016
$4.3MRole of Circulating suPAR in FSGSR01DK101350 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI REISER, JOCHEN · 2013 to 2017
$2.6MNCRR NIH HHS UL1 RR025008NHLBI NIH HHS P01 HL086773NHLBI NIH HHS P01 HL101398NHLBI NIH HHS P20 HL113451NHLBI NIH HHS R01 HL089650NHLBI NIH HHS R01 HL095479NHLBI NIH HHS R56 HL126558NHLBI NIH HHS U10 HL110302NIA NIH HHS RF1 AG051633NIDDK NIH HHS DP3 DK094346NIDDK NIH HHS R01 DK087961NIDDK NIH HHS R01 DK101350NIDDK NIH HHS R01 DK106051NIDDK NIH HHS R01 DK108803NIDDK NIH HHS U01 DK085689NINDS NIH HHS R01 NS064162
Abstract
Soluble urokinase plasminogen activator receptor (suPAR) independently predicts chronic kidney disease (CKD) incidence and progression. Apolipoprotein L1 (APOL1) gene variants G1 and G2, but not the reference allele (G0), are associated with an increased risk of CKD in individuals of recent African ancestry. Here we show in two large, unrelated cohorts that decline in kidney function associated with APOL1 risk variants was dependent on plasma suPAR levels: APOL1-related risk was attenuated in patients with lower suPAR, and strengthened in those with higher suPAR levels. Mechanistically, surface plasmon resonance studies identified high-affinity interactions between suPAR, APOL1 and α
Indexed as
AdolescentAdultAgedAllelesAnimalsApolipoprotein L1ApolipoproteinsBlack or African AmericanCohort StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansIntegrin alphaVbeta3Lipoproteins, HDLMaleAPOL1 protein, humanApolipoprotein L1ApolipoproteinsIntegrin alphaVbeta3Lipoproteins, HDLReceptors, Urokinase Plasminogen Activator
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.